z-logo
open-access-imgOpen Access
Identification of antibody epitopes in the CB‐11 peptide of bovine type II collagen recognized by sera from arthritis‐susceptible and ‐resistant rhesus monkeys
Author(s) -
TURNER S.,
BAKKER N. P. M.,
HART B. A.,
HOLT P. J. L.,
MORGAN K.
Publication year - 1994
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1994.tb06553.x
Subject(s) - epitope , antibody , type ii collagen , cyanogen bromide , peptide , linear epitope , biology , microbiology and biotechnology , peptide sequence , antigen , epitope mapping , virology , arthritis , chemistry , immunology , biochemistry , gene
SUMMARY Sera from eight rhesus monkeys that had been immunized with native bovine type II collagen were tested for antibodies to cyanogen bromide peptides (CB peptides) of type II collagen by Western blotting. The monkeys produced IgG antibodies to a number of different CB peptides, with five out of eight animals producing antibodies to the CB‐11 peptide (four arthritic, one non‐arthritic). Antibody epitopes on the CB‐11 peptide of bovine type II collagen recognized by these sera were investigated by epitope mapping. Peptides (8‐mers overlapping by seven amino acids) representing the CB‐11 region were synthesised and the sera screened for binding to these peptides to determine areas of high IgG antibody binding to this region of type II collagen. The profiles obtained were not identical, though there were some epitopes that were commonly recognized. Antibodies to one epitop, also present in human type II collagen, were found only in the sera of two animals with the severest arthritis. The technique of epitope mapping has successfully identified a number of epitopes within the CB‐11 peptide of type II collagen recognized by antibodies from bovine type II collagen‐immunized monkeys. Studies on the relevance of responses to the identified epitopes can now be undertaken.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here